Owkin is a French-American startup that deploys AI and Federated Learning for medical research. The company deploys AI and federated learning for medical research and aims to empower researchers in hospitals, universities, and pharmaceutical companies to understand why drug efficacy varies from patient to patient, enhance the drug development process, and identify the best drug for the right patient to improve treatment outcomes. It is backed by investors such as F-Prime Capital & Eight Roads Ventures, GV, Otium Ventures, Cathay Innovation, and NJF Capital as well as a scientific board.

It was co-founded in 2016 by Thomas Clozel, a hematologist oncologist and researcher, and Gilles Wainrib, a computer science teacher-researcher in New York, New York. We combine cutting-edge machine learning and biology to advance drug discovery. We blend human insight with safe and fast data access to train high-performance models. Our cutting-edge machine learning methodologies de-risk and accelerate clinical trials. Building useful clinical tools to identify patients and boost their access to better treatment options.